Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer

Eun-Sun Choi1*, Jeong-Seok Nam2*, Ji-Youn Jung3, Nam-Pyo Cho4 & Sung-Dae Cho4

1Division of High-risk Pathogen Research, Korea Centers for Disease Control and Prevention, Osong, Republic of Korea, 2Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Graduate School of Medicine, Incheon 406-840, Korea, 3Department of Companion and Laboratory Animal Science, Kongju National University, Yesan 314-701, Republic of Korea, 4Department of Oral Pathology, School of Dentistry and Institute of Biodegradable Material, Institute of Oral Bioscience, Brain Korea 21 Project, Chonbuk National University, Jeonju 561-756, Republic of Korea.

Cervical cancer is the third most common cancer and the third leading cause of death among women. However, the standard treatment for cervical cancer includes cisplatin, which can cause side effects such as hematological damage or renal toxicity. New innovations in cervical cancer treatment focus on developing more effective and better-tolerated therapies such as Sp1-targeting drugs. Previous studies suggested that mithramycin A (Mith) inhibits the growth of various cancers by decreasing Sp1 protein. However, how Sp1 protein is decreased by Mith is not clear. Few studies have investigated the regulation of Sp1 protein by proteasome-dependent degradation as a possible control mechanism for the regulation of Sp1 in cancer cells. Here, we show that Mith decreased Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. We found that prolonged Mith treatment was well tolerated after systemic administration to mice carrying cervical cancer cells. Reduction of body weight was minimal, indicating that Mith was a good therapeutic candidate for treatment of cancers in which Sp1 is involved in promoting and developing disease.

Cancer initiation and progression are mediated through dysregulation of multiple signaling pathways. Therefore, the potential therapeutic effects achievable by targeting individual signaling pathways may be largely limited1. Targeting the divergence points of diverse signaling pathways may represent a promising therapeutic strategy for various cancers. Targeting transcription factors is particularly attractive because they are nodal points of multiple signaling pathways and are commonly deregulated in cancer2. Inhibition of excessive oncogenic transcription factor activity could be an effective strategy for new chemotherapeutic agents.

Specificity protein 1 (Sp1) is a zinc-finger transcription factor that regulates multiple cellular functions and promotes tumor progression by controlling expression of genes involved in cell cycle3, apoptosis4 and DNA damage5. Several studies demonstrated that Sp1 binds to GC-rich motifs of promoters and interacts with components of the general transcriptional machinery and co-activator complexes of multiple signaling pathways6. Increasing evidence suggests that aberrant expression or activity of Sp1 occurs in various cancers types6. Suppression of Sp1 levels reduces tumor growth in mice implanted with lung cancer cells7. Sp1 is directly involved in nicotine-induced lung cancer cell growth8. Therefore, it would be worthwhile to test promising cancer therapeutic drugs targeting Sp1 with less cytotoxic potency.

Mith, a selective Sp1 inhibitor, is a natural polycyclic aromatic polyketide isolated from Streptomyces strains9. Mith is used clinically as a chemotherapeutic agent to treat several cancer types including testicular carcinoma10 and chronic myeloid leukemia11. Mith inhibits binding of Sp1 to promoters, thereby inhibiting proto-oncogenes such as ha-RAS12 and c-Myc13; anti-apoptotic genes such as survivin14 and XIAP15; and pro-angiogenic genes such as VEGF16. However, regulation of Sp1 levels by proteasome-dependent degradation has not been investigated as a possible mechanism for controlling the amount of Sp1 in cancer cells. Here, we show that Mith decreased Sp1 protein levels by inducing proteasome-dependent degradation in cervical cancer cells.

Cervical cancer is a primary cancer of the uterine cervix and the second most common cancer diagnosed in women after breast cancer17. Although mortality rates have steadily decreased over the past decades because of early detection and screening, many patients have an unfavorable prognosis18. Cisplatin-based chemotherapy is gold standard treatment for metastatic cervical cancer19. However, cisplatin administration can cause gastro-
intestinal, hematological, or renal toxicity. Cisplatin-induced toxicity often requires dose reduction, treatment delay, or discontinuation of therapy. Thus, finding less toxic and more effective targets and therapeutic drugs to treat cervical cancer is highly desirable.

In this study, we demonstrated that Mith significantly inhibited cervical cancer growth in vitro and in vivo. At the molecular level, Mith dramatically induced Sp1 degradation in a proteasome-dependent manner and suppressed growth of cervical cancer cells through a DR5/caspase-8/Bid signaling pathway. Taken together, our results support the hypothesis that suppression of cellular Sp1 levels by Mith is an effective therapeutic strategy for cervical cancer.

**Methods**

**Antibodies and Reagents.** Antibodies against cleaved caspase-3, 8, 9, PARP, Bax, Bak, Bad, Bim, Puma, Bcl-2, Bcl-xL, Mcl-1, DR5, DR4 and phospho-eIF4E were from Cell Signaling (Danvers, MA, USA) and Cox4 antibody was from Abcam (Cambridge, UK); cytochrome C antibody was from BD Biosciences (San Diego, CA, USA); MG-132 and antibodies for Sp1, α-tubulin and actin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); DAPI, CHX and Mith was from Sigma-Aldrich Chemical Co. (St Louis, MO, USA); zVAD-fmk, a pancaspase inhibitor, was from R&D Systems (Minneapolis, MN, USA).

**Cell culture and Drug treatment.** HEp-2 cells were from Kyungpook National University (Daegu, Korea) and KB cells were from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in DMEM 100 U/mL each of penicillin and streptomycin and 10% FBS for HEp-2 cells and 5% FBS for KB in a humidified atmosphere containing 5% CO2 at 37°C and streptomycin and 10% FBS for HEp-2 cells and 5% FBS for KB. Cells were exposed to DMSO or Mith for 48 h, washed with 2 mL ice-cold phosphate buffered saline (PBS), dislodged with trypsin, and pelleted by centrifugation for 3 min at 800 rpm. Total attached cells were counted using a Neubauer’s chamber (hemocytometer).

**Preparation of cytosol and mitochondrial fraction.** Cytosolic and mitochondrial fractions were isolated by digitonin or Triton X-100. HEp-2 and KB cells were washed with ice-cold PBS and fixed with 1 mL methanol solution at room temperature (RT) for 10 min. Fixed cells were stained with DAPI (2 μg/mL) solution and deposited on slides at RT in the dark. DAPI-stained cell morphology was observed under a fluorescence microscope.

**Measurement of mitochondrial membrane potential.** The mitochondrial membrane potential (ΔΨm) was determined using the mitochondria-specific lipophilic, cationic fluorescent compound JC-1 (Stratagene, La Jolla, CA, USA). HEp-2 and KB cells were seeded into 60 mm2 dishes. After treatment, cells were washed with PBS, dislodged with trypsin, and pelleted by centrifugation for 3 min at 800 rpm. Pellets were resuspended in 500 μL 1X JC-1 staining reagent at 37°C for 30 min, followed by washing with ice-cold PBS. Cell-associated fluorescence was measured with fluorescence plate reader.

**Western blot analysis.** Whole cell lysates were extracted with lysis buffer and protein concentrations were measured by the bicinchoninic acid (BCA) method using bovine serum albumin as a standard. Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked and probed with primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies. Blots were developed using chemiluminescence and scanned using a digital camera. Band intensities were quantified using ImageJ software.

**Figure 1** | Effect of Mithramycin A (Mith) on cell viability and apoptosis in HEp-2 and KB cells. HEp-2 and KB cells were treated with or without Mith for 48 h. (A) Cell numbers were obtained by direct cell counting with a hemocytometer. (B) By fluorescence microscopy (magnification X400), HEp-2 and KB cells exhibited nuclear fragmentation and condensation after DAPI staining. (C) HEp-2 and KB cells were treated with Mith as indicated for 48 h before western blots of whole cell lysates detected caspase 3, poly(ADP-ribose) polymerase (PARP) and cleavage of caspase 9. (D) HEp-2 and KB cells were preincubated with pancaspase inhibitor Z-VAD-fmk for 1 h before Mith treatment and western blot to detect cleaved PARP. β-actin was the internal control. Results are mean ± SD from three independent experiments. * P < 0.05.
Figure 2 | Effect of Mith on a mitochondria-mediated apoptotic pathway. HEp-2 and KB cells were treated with or without Mith for 48 h. (A) Cytochrome c release in Mith-induced apoptosis was evaluated by analyzing cytosolic fractions for cytochrome c by western blot with α-tubulin as internal control for cytosolic fraction and COX4 exclusive mitochondria marker as control for separation of mitochondrial and cytosolic fractions. (B) Western blot of HEp-2 and KB cells for total and truncated Bid. (C) Alteration of ΔΨm after exposure of HEp-2 and KB cells to Mith at indicated concentrations, measured with JC-1 probe as average ratio of red:green fluorescence. (D) DR5 and cleaved caspase-8 by western blot with β-actin as internal control. Results are mean ± SD from three independent experiments. * P < 0.05.

Reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA was extracted from Hep-2 and KB cells using easy-BLUE Total RNA Extraction Kits (iNtRON, Daejeon, Korea) following the manufacturer’s recommendations. For reverse transcriptase polymerase chain reaction (RT-PCR), 2 μg total RNA was mixed with diethylpyrocarbonate (DEPC)-treated water for a total volume of 20 μL in Maxime PreMix Kit buffer. Reverse transcription was 60°C for 1 h and inactivation of RTase was 96°C for 5 min. Target cDNA was amplified using primers: sense 5’-ATG GGG GCA ATG GTA ATG GTG G-3’ and antisense 5’-TCG CTT AAT GTC ACG CAC GAT TTC-3’. Bands were visualized by an LAS-500 imaging system.

Sp1 small interfering RNA. On TARGET plus SMART-pool small interfering RNA (siRNA) sequences targeting Sp1 and non-targeting control were purchased from Dharmacon Research (Lafayette, CO, USA). Transfection was according to the manufacturer’s instructions. HEp-2 and KB cells were seeded at 50%–60% confluence in 6-well plates and transfected transiently with 25 or 50 nM siRNA using DharmaFECT2 transfection reagent (Thermo Scientific, Lafayette, CO, USA). After transfection for 6 or 48 h, HEp-2 and KB cells were analyzed for apoptotic effects using western blots and DAPI staining.

Nude mouse xenograft. Female nude mice were from Orient Ltd. (Suwon, Korea). All animal studies were conducted according to protocols approved by the Institutional Animal Care and Use Committee of the university. KB cells were suspended in sterile PBS and injected subcutaneously into the right flank of mice. Mice were randomized into two groups containing five mice each and treated with 0.2 mg/kg/day of Mith (i.p.) three times per week for 29 days. Control mice received an equal volume of vehicle. After 29 days, bodies, organs and tumors were weighed and tumor volumes determined. Tumors were measured along the two diameter axis with calipers to allow calculation of tumor volume as V = π/6(D + d/2)^2, where D and d are larger and smaller diameters, respectively.

TUNEL assay. Tumor tissues were examined using a Dead-End Colorimetric TUNEL System (Promega) according to the manufacturer’s instructions. After dewaxing and rehydration, tissue sections were counterstained with methyl green. Brown apoptotic bodies in tumor sections of control and Mith-treated mouse samples were counted using a Nikon Eclipse E800 microscope (Nikon Inc. Melville, NY, USA).

Histopathological examination. Tumors and liver, kidney, heart, lung and brain were fixed in 10% neutral buffered formalin, embedded, sectioned (5 μm) and stained with hematoxylin and eosin (H&E). Histopathological changes were observed using a Nikon Eclipse E800 microscope.

Immunohistochemistry. Tissue sections were fixed with 10% formaldehyde, embedded in paraffin and cut into 4 mm sections. Sp1 staining used Envision kits (DAKO, Carpinteria, CA, USA). Sections were deparaffinized with xylene, dehydrated with ethanol and heated in 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase was inactivated with 3% H2O2 for 10 min at RT and sections were blocked with 3% normal goat serum in 0.2 M PBS (pH 7.4). Samples were incubated with anti-Sp1 at RT for 1 h. Secondary antimouse antibody-coated polymer peroxidase complexes (DAKO) were applied for 30 min at RT, followed by treatment with substrate/chromogen (DAKO) and incubation for 5–10 min at RT. Slides were counterstained with hematoxylin.
Statistical analysis. Quantitative data were presented as mean ± SD and were analyzed by Student’s two-tailed t-test. A value of \( p < 0.05 \) was considered statistically significant.

Results

Mith dose-dependently inhibits growth and induces apoptosis in cervical cancer cells. To assess the antiproliferative effects of Mith on cervical cancer cells, two cervical cancer cell lines with different genetic backgrounds were grown with or without treatment with Mith at different concentrations. Mith inhibited HEp-2 and KB cell growth in a concentration-dependent manner after 48 h (Fig. 1A). Apoptotic cell death was qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Mith led to significant DNA fragmentation compared to untreated controls (Fig. 1B). Western blots revealed that Mith treatment induced activation of initiator (caspase-9), effector caspases (caspase-3), and PARP (substrate for caspase-3) in both HEp-2 and KB cells (Fig. 1C). To determine if Mith-induced cell death was dependent on caspase activation, HEp-2 and KB cells were preincubated with the broad-spectrum caspase inhibitor zVAD-fmk before Mith exposure. Pretreatment of cells with zVAD-fmk attenuated Mith-induced PARP cleavage, suggesting that Mith induced caspase-dependent apoptosis in both HEp-2 and KB cells (Fig. 1D).

Mith induces mitochondria-mediated apoptosis through DR5/caspase-8/Bid signaling. The above results implicated caspase 9-dependent mitochondrial apoptotic pathways. Therefore, we investigated the distribution of cytochrome c in response to Mith treatment. Cytochrome c was released from mitochondria into the cytosol by Mith in a concentration-dependent manner (Fig. 2A). In apoptotic signaling, the BH3-only protein Bid triggers Bak or Bax dimerization, leading to cytochrome c release. In both cervical cancer cell lines, Mith induced Bid truncation at 48 h of treatment (Fig. 2B). We further examined if other anti-apoptotic or pro-apoptotic proteins in the Bcl-2 family responded to Mith in cervical cancer cells. Levels of the pro-apoptotic proteins Bak and Bad significantly increased in KB cells as compared to Hep2 cells (Suppl. Fig. 1). Because a postulated mechanism by which activation of Bid causes cytochrome c release involves changes in \( \Delta \Psi_m \), its status in cervical cancer cells before and after Mith treatment was investigated. HEp-2 and KB cells were incubated with JC-1, a fluorescent probe used to measure \( \Delta \Psi_m \) variations. Mith-treated cells showed a concentration-dependent, rapid, strong decrease in fluorescence intensity (Fig. 2C). Bid is a downstream target of activated caspase-8 death mediated by DR4 or DR5 receptors in certain cancers. Therefore, we investigated whether the levels of DR4, DR5 and cleaved caspase-8 were modulated by Mith treatment. Mith treatment significantly increased the cleaved caspase-8 and DR5 levels compared with negative controls (Fig. 2D). Taken together, these results indicated that Mith induced mitochondria-mediated apoptosis through a DR5/caspase-8/Bid signaling pathway in cervical cancer cells.

Mith induces proteasome-dependent Sp1 degradation. Previous studies suggest that Mith inhibits growth of human cancers by decreasing Sp1 protein, but how Sp1 protein is decreased by Mith is not clear. We checked Sp1 mRNA levels in cervical cancer cell lines and saw no significant difference in cells with or without Mith treatment (Fig. 3A). Therefore, we determined if Mith regulated Sp1 protein levels. Mith treatment significantly reduced Sp1 protein in HEp-2 and KB cells (Fig. 3B). To further assess whether Mith affected initiation of Sp1 protein synthesis, HEp-2 and KB cells were incubated with the protein synthesis inhibitor cycloheximide (CHX) before treatment with Mith. CHX treatment did not result in...
any significant differences in cellular Sp1 levels (Fig. 3C). This result suggested that Sp1 turnover might be related to increased protease activity. Therefore, to determine if decreased levels of Sp1 could be rescued by protease inhibitors, HEp-2 and KB cells were pretreated with the proteasome inhibitor MG132 before Mith treatment. MG132 rescued Sp1 from Mith-induced protein degradation (Fig. 3D), indicating that Mith induced proteasome-dependent Sp1 degradation.

Mith synergized with Sp1 knockdown to induce apoptosis. Previous studies have suggested that Mith inhibits the growth of various human cancers by decreasing Sp1 protein level23–25, but it is still not clear how Sp1 protein level is decreased by Mith. We first checked the mRNA expression levels of Sp1 in different cervical cancer cell lines. No significant difference in the Sp1 mRNA levels was observed in cervical cancer cells with or without Mith treatment (Fig. 3A). Therefore, we next determined whether Mith could regulate Sp1 protein levels. Mith treatment significantly reduced Sp1 protein levels in HEp-2 and KB cell (Fig. 3B). To further assess whether Mith had an effect on the initiation of Sp1 protein synthesis, HEp-2 and KB cell were incubated with the protein synthesis inhibitor cycloheximide (CHX) prior to treatment with Mith. CHX treatment did not result in any significant difference in cellular Sp1 levels (Fig. 3C). The independence of Sp1 degradation upon protein synthesis suggested that Sp1 turnover may be related to increased protease activity. Therefore, to determine whether the decreased levels of Sp1 could be rescued by protease inhibitors, HEp-2 and KB cells were pretreated with the proteasome inhibitor MG132 prior to treatment with Mith. MG132 rescued Sp1 from Mith-induced protein degradation (Fig. 3D), indicating that Mith induces Sp1 degradation in a proteasome-dependent manner.

Mith synergized with Sp1 knockdown to induce apoptosis. In a Mith-induced apoptosis model, reduced Sp1 protein levels were observed earlier than other mitochondria-mediated apoptosis regulators, specifically DR5, caspase-8, caspase-3 and PARP (Suppl. Fig. 2). We therefore hypothesized that Sp1 might act as a direct upstream regulator of the DR5/caspase-8/Bid signaling pathway. To address more specifically the direct regulatory roles of Sp1 in Mith-mediated DR5/caspase-8/Bid signaling pathway, endogenous Sp1 was knocked down in HEp-2 and KB cells by siRNA. Western blots confirmed reduction of Sp1 protein levels

---

**Figure 4** | Knockdown of transcription factor Sp1 is synergistic with Mith apoptotic effects. Cells were transiently transfected with control siRNA (siCon) or Sp1-specific siRNA specific (siSp1) for 48 h. (A) Cell viability was determined using MTS assays. (B) By fluorescence microscopy (magnification X400), HEp-2 and KB cells exhibited nuclear fragmentation and condensation after DAPI staining. (C) Bid, DR5, and cleaved caspase-8 were detected by western blot. (D) HEp-2 and KB cells were transiently transfected with Sp1 siRNA for 48 h before Mith treatment. Sp1, DR5, Bid, cleaved caspase-8, cleaved PARP were analyzed by western blot with β-actin as internal control. Results are mean ± SD from three independent experiments. *P < 0.05.
Results are mean ± SD from three independent experiments. * P < 0.05.

Figure 5 | Inhibition of tumor growth by Mith in nude mice xenografted with KB cells. Mice were treated with 0.2 mg/kg/day Mith (i.p.) three times per week for 29 days. (A, B) Treatment with 0.2 mg/kg/day of Mith significantly reduced average tumor volume and weight compared to PBS controls. (C) Representative sections from tumor xenografts from treated mice stained for TUNEL showing cells with fragmented DNA after Mith treatment and the third leading cause of death26. The standard treatment for cervical cancer is the third most common cancer among women per year and cervical cancer is responsible for 274,000 deaths. Cervical cancer is cisplatin-based chemotherapy after surgery, which usually yields positive results in initial treatment27. In many cases, however, chemoresistance is induced by prolonged cisplatin-based treatment, which has significant toxicity28. Although the effects of other chemotherapy drugs including ifosfamide, paclitaxel, and topotecan have been assessed as single drugs or in a combination of drugs, chemotherapy results remain unsatisfactory29. Therefore, innovations in cervical cancer treatment mainly aim for more therapies that are effective and better tolerated than existing choices. Sp1-targeted drug is an attractive option for cervical cancer treatment.

Mith is a FDA-approved chemotherapeutic agent that is effective against testicular carcinoma and chronic myeloid leukemia. In a clinical investigation of 305 patients with testicular tumors treated with Mith, 10.8% of patients (33 patients) showed a complete disappearance of tumor in testis and an additional 26.2% of patients (80 patients) was responded with significant regression of tumor in multiple site30. In other clinical trials of 13 patients with accelerated phase of chronic myeloid leukemia, 2 patients had been stabilized, 3 patients had partial responses, and 1 patient had a complete response with a major cytogenic response31. Recently, our group reported the antitumor effects Mith on human prostate29 and oral30 cancer cells in vitro and in vivo. In addition, recent studies suggest that Mith sensitizes cancer cells to tumor necrosis factor (TNF)-induced apoptosis and suppresses p53-mediated transcriptional responses32. Mith, in part, binds selectively to GC-rich sequences in the DNA minor groove and preferentially blocks binding of transcription factors such as Sp1 to guanosine-cytosine (G-C)-rich elements in target gene promoters33. Sp1 regulates several cellular functions and influences tumor growth by controlling expression of genes related to tumor growth and development such as cyclin D1, c-Jun, and c-Myc34. Previous studies indicate that Sp1 accumulates in tumors cervical tissue35. Both stability and transcriptional activity contribute to enhanced Sp1 protein levels observed during tumorigenesis36. Previous studies suggest that Mith inhibits the growth of various human cancers by decreasing Sp1 protein37,38, but how Sp1 protein is decreased by Mith is unclear. Many transcription factors can be degraded by the proteasome39. In many cases, domains of transcriptional activation and degradation signals directly overlap. However,

Discussion

Nearly half a million new cervical cancer cases occur among women each year and cervical cancer is responsible for 274,000 deaths. Cervical cancer is the third most common cancer among women and the third leading cause of death40. The standard treatment for cervical cancer is cisplatin-based chemotherapy after surgery, which usually yields positive results in initial treatment27. In many cases, however, chemoresistance is induced by prolonged cisplatin-based treatment, which has significant toxicity28. Although the effects of other chemotherapy drugs including ifosfamide, paclitaxel, and topotecan have been assessed as single drugs or in a combination of drugs, chemotherapy results remain unsatisfactory29. Therefore, innovations in cervical cancer treatment mainly aim for more therapies that are effective and better tolerated than existing choices. Sp1-targeted drug is an attractive option for cervical cancer treatment.

Mith is a FDA-approved chemotherapeutic agent that is effective against testicular carcinoma and chronic myeloid leukemia. In a clinical investigation of 305 patients with testicular tumors treated with Mith, 10.8% of patients (33 patients) showed a complete disappearance of tumor in testis and an additional 26.2% of patients (80 patients) was responded with significant regression of tumor in multiple site30. In other clinical trials of 13 patients with accelerated phase of chronic myeloid leukemia, 2 patients had been stabilized, 3 patients had partial responses, and 1 patient had a complete response with a major cytogenic response31. Recently, our group reported the antitumor effects Mith on human prostate29 and oral30 cancer cells in vitro and in vivo. In addition, recent studies suggest that Mith sensitizes cancer cells to tumor necrosis factor (TNF)-induced apoptosis and suppresses p53-mediated transcriptional responses32. Mith, in part, binds selectively to GC-rich sequences in the DNA minor groove and preferentially blocks binding of transcription factors such as Sp1 to guanosine-cytosine (G-C)-rich elements in target gene promoters33. Sp1 regulates several cellular functions and influences tumor growth by controlling expression of genes related to tumor growth and development such as cyclin D1, c-Jun, and c-Myc34. Previous studies indicate that Sp1 accumulates in tumors cervical tissue35. Both stability and transcriptional activity contribute to enhanced Sp1 protein levels observed during tumorigenesis36. Previous studies suggest that Mith inhibits the growth of various human cancers by decreasing Sp1 protein37,38, but how Sp1 protein is decreased by Mith is unclear. Many transcription factors can be degraded by the proteasome39. In many cases, domains of transcriptional activation and degradation signals directly overlap. However,
regulation of Sp1 protein levels via proteasome-dependent degradation as not been studied as a mechanism for controlling the amount of Sp1 in cancer cells. Here, we show that Mith decreased Sp1 protein levels by inducing proteasome-dependent degradation. The proteosome inhibitor MG132 rescued Sp1 from Mith-induced protein degradation, indicating that Mith induced degradation via proteasome.

In this study, we investigated the antitumorigenic activity of Mith in cervical cancer cell lines and cervical tumor xenografts. Systemic toxicity that causes acute and chronic organ damage is a major limitation to the clinical application of Mith. Therefore, we assessed the doses at which Mith could be safely administered to mice. Evaluation of multiple organ toxicity revealed that prolonged Mith treatment (0.2 mg/kg) was well tolerated with minimal reduction of body weight upon systemic administration to cervical cancer-bearing mice. Along with recent studies on breast37, prostate29, and ovarian cancers38, our results suggest that Mith is be a good therapeutic candidate for treatment of cancers in which Sp1 is important for promoting and developing disease.

Recent data suggest that induction of tumor cell death by stimulating mitochondrial and death receptor-mediated apoptotic pathways might contribute more to chemoresistance than previously thought31,39. Therefore, strategies to increase death receptor (DR5)-mediated apoptosis, for example by Mith, might be useful for treatment of chemoresistant cancers. In this study, the apoptotic response to Mith was accompanied by activation of a mitochondria-mediated apoptotic pathway through DR5/caspase-8 signaling. This phenomenon might also explain in part how Mith increases cell sensitivity to TNF-α40, as caspase-8 is implicated in TNF-mediated and death receptor-mediated apoptotic pathways40. Several regulators and effectors controlling the DR5-mediated apoptotic pathway might be involved in Mith-induced apoptosis. Our hypothesis for Mith function in mediating cervical cancer cell apoptosis is modulation of BID expression. Truncated (t)BID, a BH3-only protein of the Bcl-2 family, triggers rapid and extensive release of cytochrome c and subsequent downregulation of apoptosome formation41. We observed that in both tested cervical cancer cell lines, Mith induced BID truncation at 48 h after treatment. Further characterization of truncated (t)BID to understand its role in Mith-induced apoptosis will be interesting for our future studies. Since Mith has been used clinically for many years to treat various cancers, the inhibitory effects of Mith on cervical cancer are intriguing and merit further study to realize the full potential of Mith in death receptor-mediated apoptosis as an novel therapeutic approach.

In conclusion, we demonstrated that Mith significantly inhibited cervical cancer growth in vitro and in vivo. At the molecular level, Mith dramatically induced proteasome-dependent Sp1 degradation, thereby suppressing growth of cervical cancer cells through a DR5/caspase-8/Bid signaling pathway. Collectively, these data provide further evidence of the relevance of Sp1 as a therapeutic target and the potential of Mith as an effective therapeutic strategy for cervical cancer.

1. Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2, 740–9 (2002).
2. Frank, D. A. Targeting transcription factors for cancer therapy. I Drugs 12, 29–33 (2009).
3. Chae, J. I., Lee, R., Cho, J., Hong, I. & Shim, J. H. Specificity protein 1 is a novel target of 2,4-bis-(p-hydroxyphenyl)-2-butanal in the suppression of human oral squamous cell carcinoma cell growth. J Biomed Sci 21, 4 (2014).
4. Lee, H. E. et al. Inhibition of specificity protein 1 by dibenzylidenecacetone, a curcumin analogue, induces apoptosis in mucosaeodermal carcinomas and tumor xenografts through Bim and truncated Bid. Oral Oncol 50, 189–95 (2014).
5. Olofsson, B. A., Kelly, C. M., Kim, J., Hornsbö, S. M. & Azizkhan-Clifford, J. Phosphorylation of Sp1 in response to DNA damage by ataxia telangietasia-mutated kinase. Mol Cancer Res 5, 1319–30 (2007).
6. Safe, S. & Abdelrahim, M. Sp transcription factor family and its role in cancer. Eur J Cancer 41, 2438–48 (2005).
7. Hsu, T. L. et al. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol Pharmacol 82, 1115–28 (2012).
8. Brown, K. C. et al. Nicotine induces the up-regulation of the α7- nicotinic receptor (α7-nAChR) in human squamous cell lung cancer cells via the Sp1/GATA protein pathway. J Biol Chem 288, 33049–59 (2013).
9. Barcelo, F. et al. DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49, 10543–50 (2010).
10. Kennedy, B. J. & Torkelson, J. L. Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 24, 327–8 (1995).
11. Dutcher, J. P., Coletti, D., Paietta, E. & Wiernik, P. H. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 21, 375–80 (1997).
12. Miura, A. et al. Regulatory mechanism of PAC1 gene expression via Sp1 by nerve growth factor in PC12 cells. FEBS Lett 566, 1731–5 (2012).
13. Reamon-Buettner, S. M. & Borlak, J. Epigenetic silencing of cell adhesion molecule candidate for treatment of cancers in which Sp1 is important for promoting and developing disease.

The proteosome inhibitor MG132 rescued Sp1 from Mith-induced protein degradation, indicating that Mith induced degradation via proteasome.
35. Wang, Y. T. et al. Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. *J Mol Biol* **380**, 869–85 (2008).
36. Lecker, S. H., Goldberg, A. L. & Mitch, W. E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. *J Am Soc Nephrol* **17**, 1807–19 (2006).
37. Cheng, H. T. & Hung, W. C. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. *Oncol Rep* **29**, 1238–44 (2013).
38. Previdi, S. et al. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. *Gynecol Oncol* **118**, 182–8 (2010).
39. French, L. E. & Tschopp, J. Protein-based therapeutic approaches targeting death receptors. *Cell Death Differ* **10**, 117–23 (2003).
40. Chinnaiyan, A. M. et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. *J Biol Chem* **271**, 4961–5 (1996).
41. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* **94**, 481–90 (1998).

**Acknowledgments**

This research was supported by the Basic Science Research Program (2013R1A1A2057882) and Basic Research Lab Program (2014R1A4A1005309) through the National Research Foundation of Korea (NRF).

**Author contributions**

E.S.C. and J.S.N. designed and performed experiments, analyzed data and wrote manuscript draft. J.Y.J. designed and performed experiments and N.P.C. and S.D.C. designed the research plan, analyzed data and finalized manuscript. All authors reviewed the manuscript.

**Additional information**

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Choi, E.-S., Nam, J.-S., Jung, J.-Y., Cho, N.-P. & Cho, S.-D. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. *Sci. Rep.* **4**, 7162; DOI:10.1038/srep07162 (2014).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/